DDI-Fusion

Predicts human DDI (midazolam AUCR) using a proprietary algorithm that takes in vitro CYP interaction data (reversible inhibition, time dependent inhibition and induction) and chemical structure as inputs. DDI-Fusion has several advantages over the regulatory mechanistic static model: (i) it uses a data-driven optimisation approach requiring fewer assumptions, (ii) human Cmax is predicted so no clinical in vivo data are required. Provides early stage filter for directing chemistry and prioritising screening.